In pancreatic cancer, a tumor type with low baseline immunogenicity, an individualized mRNA neoantigen vaccine induced neoantigen-specific CD8+ T cells in 8 (50%) of 16 resected patients [20]. This evidence concerns the gene CD8A and pancreatic neoplasm.